Welcome to our dedicated page for Syra Health news (Ticker: SYRA), a resource for investors and traders seeking the latest updates and insights on Syra Health stock.
Syra Health Corp. reports news as an integrated healthcare solutions company serving government, public-sector, and commercial healthcare organizations. Its updates center on prevention-focused and access-oriented solutions, including Population Health programs, healthcare analytics, HIPAA-compliant digital health tools, health education, training, and healthcare workforce solutions.
Recurring company developments include quarterly and annual financial results, margin and profitability trends, Population Health revenue growth, customer demand from state health departments and private-sector organizations, and cost-management initiatives. Syra Health also reports governance and leadership changes, information-security milestones such as ISO 27001:2022 certification, and operating risks tied to government healthcare budgets and contract timing.
Syra Health (OTCQB: SYRA) reported its first profitable quarter in Q1 2026, with net income $240,979 and EPS $0.02. Revenue was $2.3M, up 22% year-over-year, driven by population health $1.8M (+46% YoY). Gross margin expanded to 42.7% (up 11 percentage points). Cash grew to $2.9M and the company reported no long-term debt. Management noted milestone-driven quarterly variability but reiterated a goal of full-year profitability.
Syra Health (OTCQB: SYRA) will report first-quarter 2026 financial results for the period ended March 31, 2026, on Thursday, May 7, 2026. The company said the results will be released in a press release before the market opens.
Investors can expect the announcement via the company’s usual public channels on that date.
Syra Health (OTCQB: SYRA) won two 2026 TechPoint Mira Awards on April 28, 2026: the BioCrossroads Life Sciences Innovation Award for Syrenity and Innovation of the Year for its technology, including SyraBot and HIPAA-compliant platforms.
The recognition highlights early clinical impact for Syrenity, multi-state expansion plans, and independent validation from a 231-submission awards program judged by industry peers.
Syra Health (OTCQB: SYRA) announced a telehealth partnership with Nora Mental Health on April 2, 2026 to integrate licensed therapists into Syra's AI-driven Syrenity behavioral health app.
The collaboration creates referral pathways from Syrenity's risk stratification to Nora's telehealth or in-person care and includes joint clinical evaluation and HIPAA-compliant data practices.
Syra Health (SYRA) reported strong FY2025 results: population health revenue grew 157% to $5.3M and net loss narrowed 76% to ($896K) from ($3.8M). EPS improved to ($0.08) from ($0.50). Operating expenses declined 37% to $3.4M and gross margin rose to 34.4% from 20.7%.
The company ended 2025 with $1.6M cash, no long-term debt, launched new contracts and pilots, submitted Syrenity to FDA TEMPO, and expects profitability by year-end 2026.
Syra Health (OTCQB: SYRA) will report fourth quarter and full year 2025 financial results on Thursday, March 12, 2026. The company said it will release results via a press release before the market opens. Investors should monitor filings and the company website for the release.
Syra Health (OTCQB: SYRA) appointed Gregory R. Alexander as Chief Executive Officer, effective January 5, 2026. Alexander is a C-suite healthcare executive with 20+ years of P&L experience and prior roles across Medicare, Medicaid, population health, and healthcare technology.
Key disclosed credentials include expanding operations from three to 11 markets at Lumeris, growing Medicare Advantage membership by over 20% annually, tripling sales at CitizensRx, and overseeing operations with revenues from $45 million to $1.5 billion. Alexander is a Carmel, Indiana resident and former U.S. Marine Corps officer.
Syra Health (OTCQB: SYRA) reported third-quarter results for the period ended September 30, 2025, highlighting improved margins and reduced losses. Q3 revenue was $1.69M, driven by a 96% YoY increase in the Population Health segment to $1,280,011. Gross margin expanded 300 basis points to 33% and net loss narrowed 46% to ($225,902) versus Q3 2024. Adjusted EBITDA improved to ($218,601). Cash totaled $1.98M with no long-term debt. Management cited cost reductions (S&A down 12%, salaries and benefits down 43%) and a major commercial win: the SyraBot chatbot is live with a managed care organization serving 400,000 members.
Syra Health (OTCQB: SYRA) announced it will report financial results for the three months ended September 30, 2025 on Wednesday, November 12, 2025. The company said results will be released via press release before the market opens.
This notice provides the reporting date and timing for investors to review Syra Health's Q3 2025 financial results when published.
Syra Health (OTCQB: SYRA) reported Q2 2025 financial results showing progress toward profitability. Revenue remained steady at $1.9 million, with Population Health segment growing 197% to $1.6 million. The company achieved significant margin improvement, with gross margin expanding 2,090 basis points to 38.7% compared to Q2 2024.
Operating expenses decreased 53% to $816,000, while net loss improved dramatically to ($64,000) from ($1.4 million) in Q2 2024. EPS improved to ($0.01) from ($0.21). The company maintains a strong balance sheet with $2.3 million in cash and no long-term debt.
Notable developments include contract negotiations for a $5.8 million mental health program in Indiana and a new $2.1 million contract with a major health insurer, marking expansion into the private sector.